OBJECTIVE-Glycosylated hemoglobin (HbA 1c ) recently has been recommended for the diagnosis of diabetes by the American Diabetes Association, but its value in the prediction of type 2 diabetes is poorly understood. In this study we evaluated how high-normal HbA 1c levels predict type 2 diabetes. RESULTS-Subjects were stratified according to baseline HbA 1c (,5.0, 5.00-5.49 [reference], 5.50-5.99, and 6.00-6.49%). Sex-and age-adjusted hazard ratios (95% CI) for type 2 diabetes were 1.11 (0.30-4.41), 1.00, 3.79 (1.79-8.06), and 12.50 (5.51-28.34), respectively. Results did not change after adjusting for several putative confounding factors and were confirmed when models with updated variables were used.
G lycosylated hemoglobin (HbA 1c ) was proposed as a reliable tool for diagnosing diabetes and identifying subjects at increased risk of type 2 diabetes (1) . In 2010, the American Diabetes Association (ADA) pointed out that prevention strategies should be particularly intensive in subjects with high-normal HbA 1c because they have the greatest risk (2), but this recommendation was based more on common sense than literature data. In fact, only few studies (3, 4) showed an elevated risk of type 2 diabetes in subjects with high-normal HbA 1c . Moreover, in these studies type 2 diabetes was self-reported during telephone interviews.
To support ADA recommendations, we evaluated diabetes risk in the 6.00-6.49% category of HbA 1c , with a more robust approach based on laboratory measurement of glycemic parameters.
RESEARCH DESIGN AND METHODS-The study was conducted within the framework of the Bruneck Study, a long-term, prospective populationbased survey of atherosclerosis and its risk factors carried out in Bruneck (northeastern Italy), with a baseline evaluation in 1990 (5). Among 1,000 randomly sampled Caucasian men and women aged 40-79 years, 936 volunteered. After excluding the few individuals with incomplete data, those with diabetes at baseline, and the very few lost to follow-up, in the remaining 842 subjects new cases of type 2 diabetes were registered in the follow-up examinations of 1995, 2000, and 2005. The protocol was approved by the ethics committee of the University of Verona. All participants gave an informed consent.
Clinical and biochemical measurements
Information about medical history, drug use, and lifestyle was collected by a questionnaire. Weight, height, waist and hip circumferences, and blood pressure were measured with standard techniques. At the baseline and follow-up examinations, venous blood was sampled in the morning after an overnight fast for laboratory measurements, including fasting plasma glucose (FPG) and HbA 1c (Diabetes Control and Complications Trial-aligned assay; equipment and reagents from BioRad, Milan, Italy, at both baseline and follow-up examinations). At both baseline and follow-up, diabetes was diagnosed when HbA 1c was $6.5% or diabetes treatment was ongoing. In a parallel analysis, diabetes was diagnosed when FPG was $7.0 mmol/L or diabetes treatment was ongoing. Details on parameters examined and analytical procedures were previously reported (5, 6) .
Statistical analysis
Subjects were stratified into four HbA 1c categories (,5.0, 5.00-5.49 [reference], 5.50-5.99, and 6.00-6.49%). The HbA 1c category 5.00-5.49% had the largest number of participants (n = 345) and was used as the reference. Hazard ratios (HRs) for type 2 diabetes in the HbA 1c categories were estimated with Cox proportional hazards models. Model 0 was unadjusted. Model 1 included age and sex. Model 2 also included LDL and HDL cholesterol, log-transformed triglycerides, BMI, waist-to-hip ratio, hypertension, family history of diabetes, education, alcohol, physical activity, and smoking. Model 3 included the variables in model 2 plus variables that are abnormal in conditions potentially affecting HbA 1c (white blood cell count, hemoglobin, ferritin, and creatinine). Additional models were run with updated variables From the 1 Section of Endocrinology and Metabolism, Department of Medicine, University of Verona, Verona, Italy; the (HbA 1c and other variables were assessed every 5 years during follow-up). In these models, baseline HbA 1c predicted diabetes in the first 5-year follow-up period, HbA 1c at the 5-year follow-up predicted diabetes in the following 5-year followup, and so forth in multivariable equations overcoming the limitations of single measures. In parallel analyses, the same models were run with impaired fasting glucose (IFG) as a risk variable, and diabetes was diagnosed with FPG at baseline and follow-up. All reported P values are two-sided. CONCLUSIONS-It is well known that HbA 1c captures chronic hyperglycemia in the prior 2-3 months, is well correlated to chronic diabetes complications, and has less preanalytical problems and biological variability than plasma glucose, with a noninferior standardization (7) . For such reasons, HbA 1c was recommended for diabetes diagnosis and risk stratification (1, 2) .
RESULTS-The
The findings of the current study confirm a progressively increased risk of type 2 diabetes across categories of HbA 1c and clearly document that subjects with high-normal HbA 1c have a strong risk of developing type 2 diabetes, even after adjusting for several putative risk factors (e.g., BMI) and potentially confounding variables (e.g., anemia). Remarkably, diabetes risk in subjects with high-normal HbA 1c is higher than in subjects with IFG.
Noteworthy, our study population was entirely Caucasian, and subjects were aged .40 years. Therefore, our findings cannot be necessarily extrapolated to other ethnicities and/or to younger subjects.
To the best of our knowledge, this study is the first to examine how baseline HbA 1c predicts HbA 1c -diagnosed diabetes. Our findings, which are consistent with those of studies based on self-reported diagnosis of diabetes (3, 4) , more strongly support the ADA recommendations of using HbA 1c for diabetes risk stratification and including subjects with high-normal levels in an effective prevention strategy. These subjects, indeed, have a high rate of progression to diabetes and deserve particular attention in order to prevent or delay the disease. Specific intervention trials, however, are needed to confirm such a conclusion because those conducted so far, based on lifestyle changes and/or drug use, recruited subjects at risk according to their plasma glucose levels and not HbA 1c .
